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Background and Objectives. We evaluated and compared the inﬂuence of treatment for atrial septal defect (ASD), patent ductus
arteriosus (PDA), and coarctation of the aorta (CoA) on serum levels of N-terminal proatriopeptide and N-terminal probrain
natriuretic peptide. Correlations between peptide levels and echocardiographic measurements were calculated. Patients and
Methods. Peptide levels were measured and echocardiography performed before and 6–12 months after treatment in 21 children
with ASD, 25 with PDA, 15 with CoA, and 76 control children. Results. ANPN levels were higher than in controls at baseline in all
patient groups, and NT-proBNP in patients with ASD and PDA. Both peptide levels were elevated 6 months after treatment
and decreased thereafter. Peptide levels were higher in patients with volume than pressure overload. They correlated with
echocardiographic measurements. At the 6-month follow-up, dimensions of the originally overloaded ventricle had normalized
onlyinpatientswithPDA.Conclusions.Afterintervention,peptidelevelsdecreasebutnormalizationtakesover6months.Thetype
of correlation between peptide levels and echocardiography varies according to the loading condition. Measurement of peptide
levels can be used for monitoring the course of a patient’s heart disease.
1.Introduction
Atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), C-type natriuretic peptide, and dendroaspis natri-
ureticpeptideformthenatriureticpeptidesystem.Theyhave
an important role in regulation of ﬂuid homeostasis, blood
pressure/vascular tone, and cardiomyocyte growth. This
system functions to retard the progression of heart failure,
oppositetotheeﬀectofneurohumoralsystemsliketherenin-
angiotensin-aldosteronesystemandthesympatheticnervous
system [1, 2].
ANP is produced primarily in the atrial myocyte and
in smaller amounts in ventricular myocytes. It appears in
fetal ventricular tissue and in hypertrophied ventricles. It
is stored as a prohormone in atrial granules and released
in response to wall stress. In the presence of heart disease,
ANP gene expression is upregulated in ventricular myocytes
[2, 3]. BNP is produced in atrial and ventricular myocytes.
In healthy people, the main site of gene expression is atrial,
but in disease states such as heart failure, ventricular gene
expression is upregulated [4, 5]. BNP is stored together with
ANP in storage granules in the atrial myocytes in the healthy
state. The stimulus for synthesis and release of BNP is wall
stress [2, 3].
Normal levels of ANP and BNP and their inactive N-
terminal fragment have been investigated using diﬀerent
methods[6–11].Foreachmethod,aspeciﬁcrangeofnormal
values exits. The levels of natriuretic peptides have been
shown to be higher immediately after birth and to decrease
thereafter, during the ﬁrst 2–4 months [10–12]. Studies
on levels of natriuretic peptides in pediatric patients with
diﬀerent types of congenital heart defects and heart failure
have been published. Unfortunately, the follow-up time in
most has been short, and study groups have consisted of2 International Journal of Pediatrics
Table 1: Characteristics of subjects in the study groups at baseline. Values are expressed as median (range).
Group N Gender (m/f) Age (years) No. of patients aged less than 6 months Weight (kg) Height (cm) BSA (m2)
Controls 76 32/44 5.4 12 20.4 113.8 0.79
(0.0–15.6) (3.1–66.5) (48.0–174.6) (0.19–1.81)
Patients 21 7/14 5.2 0 20.0 105.1 0.78
with ASD (2.3–14.9) (12.4–59.0) (83.0–163.0) (0.53–1.63)
Patients 25 11/14 2.6 0 13.0 87.5 0.54
with PDA (1.0–10.6) (6.9–32.8) (70.0–139.5) (0.36–1.14)
Patients 15 8/7 2.0 7 14.0 91.5 0.59
with CoA (0.0–15.5) (3.4–56.6) (49.5–164.0) (0.20–1.57)
ASD: atrial septal defect; BSA: body surface area; CoA: coarctation of the aorta;
PDA: patent ductus arteriosus.
diﬀerent types of congenital heart defects [13–16]. To our
knowledge, comparison of the eﬀect of treatment for various
types of loading conditions on levels of natriuretic peptides
has not been performed.
Atrial septal defect (ASD) predisposes the patient to
volume overload of the right side of the heart, increased
pulmonary vascular resistance, and atrial arrhythmias [17,
18]. The physiological sequelae of ASD depend on the size
of the defect, the relation of the diastolic compliances of the
right(RV)andleftventricle(LV),andtheratioofpulmonary
to systemic vascular resistance [17]. Patent ductus arteriosus
(PDA) causes volume overload of the left side of the heart
[19] and predisposes the patient to pulmonary hypertension.
Coarctation of the aorta (CoA) causes pressure overload of
the LV and predisposes the patient to systemic hypertension
[20], which may lead to myocardial hypertrophy and dias-
tolic and systolic dysfunction [21].
The timing of treatment for congenital heart defect is
based on the hemodynamic and anatomic situation, with
consideration of myocardial cell adaptation and chamber
remodeling. Therefore, it is important to have multiple
methods available for follow-up. The combination of new
imaging modalities and measurement of serum levels of
natriuretic peptides may allow us to improve evaluation of
cardiac function and timing of interventions.
N-terminal proatriopeptide (ANPN) and N-terminal
probrain natriuretic peptide (NT-proBNP) may have diﬀer-
ent regulation of gene expression depending on the form
and localization of the stress exerted on the heart. Therefore,
treatment for diﬀerent types of loading condition may
cause diﬀerent types of changes in levels of these peptides.
The purpose of this study was to evaluate the inﬂuence
of treatment for diﬀerent loading conditions on serum
levels of ANPN and NT-proBNP. We correlated peptide
levels to two-dimensional (2D) and three -dimensional (3D)
echocardiographic ﬁndings in these conditions.
2. Methods
This prospective follow-up study was carried out at the Hos-
pital for Children and Adolescents, University of Helsinki,
Helsinki, Finland, between February 2003 and February
2006. All parents agreed to have their children participate in
this clinical trial approved by the hospital ethics committee
and gave their written informed consent.
The study groups consisted of 61 patients undergoing
percutaneous or surgical treatment for ASD, PDA, or CoA.
Twenty-one patients had an ASD, 25 a PDA, and 15 a CoA.
The control group comprised 76 healthy voluntary children
of whom 64 were 6 months or older. Demographics of
children with ASD, PDA, CoA, and controls are shown in
Table 1.
All patients and controls underwent clinical cardiovascu-
lar examination and blood test sampling for measurement
of natriuretic peptides at the time of echocardiographic
examinations. All patients were examined just prior to the
intervention and 6 months later. The children with ASD and
CoA were also examined 12 months after intervention. Con-
trol children were examined once. They were asymptomatic
and showed no abnormalities in clinical examination, ECG,
or echocardiography.
Serum samples were frozen at −20◦C. Serum concen-
trations of ANPN were measured by immunoﬂuorometric
assay.ThereagentsweremanufacturedbyMedixBiochemica
(Espoo,Finland)andtheinstrumentsbyDelﬁaResearchFlu-
orometer (Wallac, Turku, Finland). Serum concentrations
of NT-proBNP were measured by the electrochemilumino-
metric method. The reagent kit was manufactured by Roche
(Mannheim, Germany), and the samples were analyzed at
Limbach Laboratory (Heidelberg, Germany).
2.1. Echocardiography. We used the Acuson Sequoia C256
echocardiography system (Siemens, Mountain View, CA)
for 2D imaging and for Doppler and M-mode measure-
ments. Three-dimensional echocardiography was performed
with TomTec computer software (TomTec Imaging Systems
GmHb, Munich, Germany). Two-dimensional echocardio-
graphic examinations were carried out by two observers (A.
Eerola and E. Jokinen). All 3D examinations and the analyses
of echocardiographic measurements were carried out by one
observer (A. Eerola).
2.2. 2D Echocardiography. Two-dimensional echocardiogra-
phy with color ﬂow Doppler was used to evaluate the
cardiac anatomy and to measure the size of ASD. M-mode
echocardiographywasperformedfromeithertheparasternalInternational Journal of Pediatrics 3
long-axis or short-axis views. RV end-diastolic and LV end-
diastolic and end-systolic dimensions were measured, and
LV volumes, fractional shortening, and ejection fraction
calculated. The z-scores of thicknesses of interventricular
septum and posterior wall of LV, and those of RV and LV
end-diastolicdimensionsweredetermined[22].Themeanof
measurements from three cardiac cycles for each participant
was saved for analysis.
2.3. 3D Echocardiography. Three-dimensional echocardio-
graphy was performed with TomTec computer software
system, as described earlier in [23]. The time-volume curves
obtained served to determine end-diastolic and end-systolic
volumes, stroke volume, and ejection fraction.
2.4. Cardiac Catheterization. Cardiac catheterization with
hemodynamic evaluation and angiography was performed
under general endotracheal anesthesia, systemic hepariniza-
tion, and antimicrobial prophylaxis. In patients with ASD,
the procedure was also guided by transesophageal echocar-
diography. For ASD closure, either the Amplatzer Septal
Occluder (AGA Medical Corp., Golden Valley, MN) or
the Helex Septal Occluder (W.L. Gore and Associates,
Flagstaﬀ,A Z )w a su s e d .T h eP D Aw a so c c l u d e dw i t he i t h e r
Flipper detachable coil (Cook, Bloomington, IN) or with an
Amplatzer Duct Occluder (AGA Medical Corp.). In patients
with CoA, percutaneous angioplasty was performed using
either balloon dilatation only or with stent implantation.
2.5. Surgery. Surgical closure of ASD was performed via
midline sternotomy with direct suture using normothermic
cardiopulmonary bypass. Repair of CoA was performed with
resection and end-to-end anastomosis from left thoraco-
tomy.
3.StatisticalAnalysis
Analyses were performed with the Statistical Package for
Social Science version 12.01 for Windows (SPSS Inc.,
Chicago, IL). For variables derived from blood samples,
median and range were calculated. Because distribution of
parameters tested by Kolmogorov-Smirnov’s goodness-of-ﬁt
test was not normal, the Mann-Whitney test was used for
statisticalanalysisbetweengroups,andtheWilcoxonSigned-
Rank Test for analysis within groups. Spearman’s correlation
coeﬃcient was used for calculating correlations between the
echocardiographic measurements of chamber dimensions
and serum concentrations of ANPN and NT-proBNP. The
level of signiﬁcance was P<. 05.
4. Results
4.1. Children with ASD. Of the 21 children with ASD, 14
were treated with device closure and 7 with operation. The
size of the defect measured a median of 12 (range 7–21)mm
in transthoracic echocardiography. No other heart defects
were observed. The ASD was closed with the Amplatzer
Septal Occluder (AGA Medical Corp., Golden Valley, MN) in
12 patients and with the Helex Septal Occluder (W. L. Gore
and Associates, Flagstaﬀ, AZ) in 2 patients. After closure, no
residual shunt was evident at the 6- or 12-month follow-up
in transthoracic echocardiography.
At baseline, children with ASD had higher serum levels
of both ANPN and NT-proBNP than controls (Figure 1;
Table 2). Six months after occlusion of ASD, the levels were
still higher than in controls. Twelve months after interven-
tion, patients no longer diﬀered from controls (Figure 1;
Table 2).
During the 12-month follow-up, the end-diastolic diam-
eter of RV decreased after intervention (Table 3). The
diﬀerence between patients and controls was signiﬁcant at
baseline and remained so up to 12 months after intervention
(Figure 2; Table 3). The end-diastolic and systolic diameter
and volume of LV increased after cessation of shunting
through ASD (Table 3). At baseline, it was smaller than that
of controls, with a median of −0.25 (range −1.75–2.00) SD
(P<. 001) but equal to controls at the 6- and 12-month
follow-ups. Similarly, the end-diastolic and systolic volumes
of LV increased in 3D echocardiography during follow-up
(Table 3).
4.2.ChildrenwithPDA. All25childrenwithPDAunderwent
percutaneous closure. In 19 children, the PDA was occluded
with a Flipper detachable coil (Cook, Bloomington, IN)
and in 7 with an Amplatzer Duct Occluder (AGA Medical
Corp., Golden Valley, MN). In these children, no other heart
defects were observed. One child had a minimal residual
shunt 6 months after coil occlusion. Children with PDA
had higher levels of ANPN and NT-proBNP than controls
before occlusion of PDA. After intervention, levels of both
peptides decreased but were still somewhat higher than in
controls at the 6-month follow-up (Figure 1, Table 2). The
LV end-diastolic and systolic diameter and volume were
higher in children with PDA than in controls at baseline, but
no diﬀerence was seen 6 months after treatment (Figure 3;
Table 3). The end-diastolic diameter of RV increased after
occlusion of PDA (Table 3).
4.3. Children with CoA. Of the 15 children with CoA, 11
had native CoA and 4 recurrent CoA after surgery. Ten
patients had a bicuspid aortic valve and one patient had
mild mitral valve regurgitation. Five patients underwent
balloon dilatation, one of them with a stent implantation.
Ten patients were operated on with resection and end-to-
end anastomosis. At baseline, the arm-leg blood pressure
gradient measured a median of 30 (range 20–56)mmHg. It
decreased to a median of 3 (range 0–16)mmHg (P = .001)
at the 6-month follow-up. Systolic blood pressure measured
amedianof120(range96–151)mmHginpatientgroupand
101 (range 72–123)mmHg in controls (P<. 001). During
the 12-month follow-up, it decreased to a median of 105
(range 83–117)mmHg in patients (P = .001 compared with
baseline) and did not diﬀer from that of controls.
At baseline, serum levels of ANPN were higher than in
controls (Figure 1; Table 2). After relief of CoA, a signiﬁcant
reduction occurred in levels of peptides as compared with4 International Journal of Pediatrics
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Figure 1:Serumlevelsof(a)N-terminalproatriopeptide(ANPN)and(b)N-terminalprobrainnatriureticpeptide(NT-proBNP)inpatients
with atrial septal defect (ASD) and patent ductus arteriosus (PDA) measured at baseline and at 6 and 12 months’ follow-up, and in controls
older than six months. Serum levels of (c) N-terminal proatriopeptide (ANPN) and (d) N-terminal probrain natriuretic peptide (NT-
proBNP) in patients with coarctation of the aorta measured at baseline and at 6 and 12 months’ follow-up, and in all controls and controls
older than six months. Whiskers at the top and bottom of each box indicate maximum and minimum; the top and bottom of each box the
third and ﬁrst quartiles; line through the box the median. Solid circles are outliers and ∗indicates an extreme case.International Journal of Pediatrics 5
Table 2: Serum levels of ANPN and NT-proBNP in patients measured at baseline and at 6 and 12 months’ follow-up, and in controls. Values
are expressed as median (range).
N ANPN (nmol/L) NT-proBNP (ng/L)
Median (range) Median (range)
Controls 76 0.30 (0.10–3.70) 68 (14–3224)
Controls 64 0.28 (0.10–0.61) 57 (14–157)
>0.5 year
ASD 21 0.44§ (0.15–1.40) 79§ (11–245)
baseline
ASD 20 0.40§ (0.17–0.71) 96§ (17–202)
6m o n t h s
ASD 21 0.31† (0.10–0.70) 58 (17–260)
1 year
PDA 25 0.37§ (0.21–1.21) 141§ (36–974)
baseline
PDA 25 0.37§† (0.14–0.58) 71§† (21–228)
6m o n t h s
CoA 15 0.60§ (0.16–16.30) 128 (5–35001)
baseline
CoA 15 0.46§† (0.09–1.20) 86§† (9–441)
6m o n t h s
CoA 13 0.34† (0.09–0.82) 60† (32–309)
12 months
ANPN: N-terminal proatriopeptide; ASD: atrial septal defect; CoA: coarctation of the aorta;
Mos: months; NT-proBNP: N-terminal probrain natriuretic peptide; PDA: patent ductus arteriosus;
§P<. 05 as compared with control group > 0.5 years except CoA group at baseline is compared with whole control group;
†P<. 05 as compared with baseline.
baseline.Atthe6-monthfollow-up,levelsofbothANPNand
NT-proBNP were higher than in controls but after one year,
the levels were similar to controls (Table 2).
Six months after treatment, the z-score of the end-
diastolic thickness of the interventricular septum had
decreased, but it increased again by the 12-month follow-up
(Figure 4). The end-diastolic diameter of RV increased dur-
ing follow-up (Table 3). In 3D echocardiography, the end-
diastolic and systolic volumes of LV remained unchanged.
4.4. Comparison of Patient Groups at Baseline. Among
patients older than 6 months, levels of NT-proBNP were the
highest in children with PDA (P = .004 as compared with
patients with CoA, P = .032 as compared with those with
ASD),followedbythosewithASD(P = nsascomparedwith
patients with CoA), and ﬁnally those with CoA. ANPN levels
at baseline were similar in all patient groups, but higher in
these than in controls.
4.5. Correlations. At baseline, serum levels of ANPN and
NT-proBNP correlated with 2D and 3D echocardiographic
dimensionsofRVandLVaccordingtotheloadingcondition.
In the ASD group, serum levels of NT-proBNP correlated
with the end-systolic volume of LV (r = 0.487, P = .025).
In patients with PDA and volume overload of the left side
of the heart, serum levels of ANPN and pro-BNP correlated
with LV end-diastolic diameter (r = 0.513, P = .009, and
r = 0.446, P = .025, resp.) and volume (r = 0.464, P = .020
and r = 0.409, P = .042, resp.) in 2D echocardiography. In
patients with CoA, negative correlations were found between
levels of ANPN and NT-proBNP and 3D echocardiographic
end-diastolic volume of LV (r =− 0.719, P = .003; and
r =− 0.744, P = .001, resp.).
5. Discussion
In this prospective follow-up study, we evaluated the inﬂu-
ence of treatment for diﬀerent types of loading conditions
on serum levels of ANPN and NT-proBNP, and correlated
peptide levels to 2D and 3D echocardiographic ﬁndings.
ANPN levels were higher than in controls at baseline in
all patient groups, and NT-proBNP in patients with ASD
and PDA. Both peptide levels were elevated 6 months after
treatment, and decreased thereafter. At the 6-month follow-
up, the patients with PDA were the only group in whom
the dimensions of the originally overloaded ventricle had
normalized. The end-diastolic diameter of RV was larger in
patients with ASD than in controls and the interventricular
septum thicker in patients with CoA than in controls.
Shunting through the ASD causes underﬁlling of the LV,
and volume overload of the RV disturbs ventricular septal
motion [24, 25]. The diastolic and systolic function of the LV6 International Journal of Pediatrics
Table 3: Two- and three-dimensional echocardiographic ﬁndings in control subjects and in groups of children with ASD, PDA, and CoA,
measured at baseline and at 6 and 12 months after repair. Values are given as median (range).
Diagnosis Controls ASD PDA CoA
baseline 6 months 12 months baseline 6m o n t h s baseline 6m o n t h s 1 2m o n t h s
f-u f-u f-u f-u f-u
N 76 21 21 25 25 15 15 13
IVSED 0.00 0.25 0.00 0.50† 0.50 0.25 1.25§ 0.50† 1.50§
(SD) (−2.00–2.75) (−1.00–3.75) (−2.00–1.25) (−1.50–2.50) (−1.75–4.50) (−1.75–4.25) (−0.75–5.00) (−1.25–2.50) (−0.00–2.75)
LVPWED −0.50 −0.25 −0.25 0.00§† −0.50 −0.25 0.25§ 0.00 0.75§
(SD) (−2.25–2.00) (−1.50–2.00) (−2.25–1.00) (−1.25–1.25) (−2.00–2.75) (−1.25–2.25) (−2.50–1.75) (−1.50–1.50) (−0.75–1.75)
RVEDD 0.25 4.75§ 1.25§† 2.25§† 0.125 0.625§† −0.375 0.75† 0.50
(SD) (−1.75–2.50) (2.25–9.75) (−1.50–5.50) (−0.25–3.50) (−1.75–2.75) (−1.75–3.50) (−2.25–1.75) (−2.00–2.00) (−2.25–1.75)
LVEDD −0.25 −1.50§ 0.00† −0.50† 0.75§ 0.00† 0.75§ 1.00§ 1.00§
(SD) (−1.75– 2.00) (−3.75–0.00) (−3.00–1.25) (−1.75–1.25) (−1.25–3.75) (−2.00–1.75) (−1.25–4.25) (−1.00–3.25) (−0.50–2.00)
LVEDV 62.1 47.2§ 63.0† 60.4† 78.4§ 64.2† 75.0§ 65.8 72.5§
(mL/m2) (36.9–87.7) (27.6–67.1) (35.5–83.1) (43.5–92.9) (44.7–117.1) (37.6–89.5) (47.9–115.6) (49.8–98.5) (52.5–82.4)
LVESV 19.3 13.2§ 18.5† 19.4† 24.5§ 19.5† 19.7 18.4 18.5
(mL/m2) (7.7–30.6) (7.4–33.2) (8.0–28.2) (12.5–31.8) (12.3–45.0) (11.9–33.3) (12.8–68.1) (8.9–37.4) (9.2–32.8)
LVED3D 56.2 49.2§ 63.5§† 65.1§† 57.5 57.7 64.7 61.4 71.4§
(mL/m2) (32.0–89.5) (31.0–65.3) (36.5–93.8) (40.0–107.6) (43.6–99.4) (41.0–84.2) (35.6–145.3) (30.7–131.1) (35.7–121.2)
LVES3D 28.5 24.1§ 31.0† 33.8§† 29.8 27.6 38.1 28.8 30.2
(mL/m2) (14.1–52.8) (16.2–38.8) (17.5–45.7) (18.1–48.9) (19.4–54.1) (18.1–37.6) (16.8–93.5) (9.3–80.1) (14.9–56.5)
ASD: atrial septal defect, CoA: coarctation of the aorta; IVSED (SD): z-score (SD) of the end-diastolic thickness of interventricular septum; LVEDD (SD): z-
score (SD) of the end-diastolic diameter of left ventricle; LVESD (SD): z-score (SD) of the end-systolic diameter of left ventricle; LVEDV: end-diastolic volume
of left ventricle adjusted for body surface area; LVESV: end-systolic volume of left ventricle adjusted for body surface area; LVED3D: end-diastolicv o l u m eo f
left ventricle adjusted for body surface area measured by 3D echocardiography; LVES3D: end-systolic volume of left ventricle adjusted for body surface area
measuredby3Dechocardiography,LVPWED(SD):z-score(SD)oftheend-diastolicthicknessofleftventricularposteriorwall;PDA:patentductusarteriosus;
RVEDD (SD): z-score (SD) of the end-diastolic diameter of right ventricle; SD: standard deviation of published normal values;
§P<. 05 as compared with control group;
†P<. 05 as compared with baseline.
canthusbemechanicallydisturbed[24].Acuteimprovement
in preload and early diastolic function of the LV after ASD
closure depends on the degree of the RV volume overload
and is associated with normalization of the ventricular septal
motion and ventricular interdependence [26]. LV symmetry
increases months after surgical ASD repair [27, 28].
In some studies, end-diastolic diameter of the RV has
decreased after ASD closure, but remained enlarged as
compared with that of controls [15, 29–32]. Some studies
have demonstrated that after closure of the defect, end-
diastolic diameters and volumes of LV and RV change
t o w a r d sn o r m a lv a l u e s[ 33, 34]. Similarly, in our patients,
size of LV increased during follow-up, and no diﬀerence
was present between patients and controls 6 months after
treatment. The end-diastolic diameter of RV decreased, but
remained larger than in controls up to 12 months after
treatment [35].
In pediatric patients with ASD, blood levels of ANPN
have been shown to correlate with the degree of shunting
[36]. After closure of ASD, levels of ANPN and volume
of RV have decreased [13]. Serum levels of ANPN have
been higher than in matched controls up to 35 years after
surgical closure of ASD [37]. On the other hand, plasma
levels of ANP and BNP have normalized during a 3-
month follow-up after device closure of ASD in children
[15]. In our study, six months after ASD closure, the
diﬀerence between patients and controls in serum levels
of ANPN and NT-proBNP was still evident, but not after
12 months. Closure of ASD redirects blood ﬂow to LV.
Therefore, in our study, the size of LV increased. This may
be why at 6 months the peptide levels had not started to
decrease.
We have earlier shown that a day after PDA occlusion,
serum levels of NT-proBNP increase, but decrease to control
levels in 6 months [23]. Our ﬁnding of the highest levels of
NT-proBNP in patients with PDA and volume overload of
LV is in accordance with the previous studies [38, 39]. To
our knowledge, no correlation between echo parameters and
peptide levels has been published in patients with left-sided
volume overload caused by PDA. In our patients with PDA,
a signiﬁcant correlation was found between serum levels of
ANPN and NT-proBNP and the end-diastolic diameter and
volume of LV.
Despite early and apparently successful repair of CoA,
myocardial hypertrophy may persist, even in the presence
of LV remodeling [40–43]. In our study, after treatment
for CoA, the thickness of the interventricular septum after
the ﬁrst 6 months decreased and the diameter of RV
increased [44]. At baseline, children with CoA had higher
levels of ANPN than controls, but the diﬀerence in levelsInternational Journal of Pediatrics 7
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Figure 2: The z-score (SD) of end-diastolic diameter of right
ventricle (RVEDD) in patients with atrial septal defect (ASD) and
in controls. Whiskers at the top and bottom of each box indicate
maximum and minimum; the top and bottom of each box the third
and ﬁrst quartiles; line through the box the median. Solid circles are
outliers.
of NT-proBNP failed to reach statistical signiﬁcance. The
diﬀerence between patients and controls in levels of both
peptides was evident at the 6-month follow-up. Serum
levels of ANPN and NT-proBNP correlated negatively
with size of LV in 3D echocardiography. This may reﬂect
diastolic ventricular dysfunction and restrictive physiology
of the ventricles even after repair, leading to dilatation of
atria.
When diﬀerent patient groups were compared at base-
line, no diﬀerences emerged in levels of ANPN and NT-
proBNP between volume and pressure overload of LV.
Volume overload of LV caused higher levels of NT-proBNP
than that of RV, but no diﬀerences in levels of ANPN were
seen. Others have found higher plasma levels of ANP in
volume overload of LV (VSD and PDA) than in right- sided
volumeoverload[12].InourpatientswithASDandCoA,no
diﬀerence was evident. The eﬀects of volume overload on the
levels of ANPN and BNP have been investigated in patients
with VSD and PDA, but no follow-up studies are available.
Plasma levels of BNP have been demonstrated to correlate
with systolic RV pressure in children with volume overload
of RV [45].
Plasma levels of BNP have been shown to correlate with
right atrial and ventricular pressures in a child population
consisting of diﬀerent loading conditions and a wide age
range [14]. In adults, plasma levels of BNP are higher
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Figure 3: The z-score (SD) of end-diastolic diameter of left
ventricle (LVEDD) in patients with patent ductus arteriosus (PDA)
andincontrols.Whiskersatthetopandbottomofeachboxindicate
maximum and minimum; the top and bottom of each box the third
and ﬁrst quartiles; line through the box the median. Solid circles are
outliers.
in patients with acquired LV dysfunction. They are also
higher in those with congenital heart defect and RV failure
than in patients without structural heart disease [46]. ANP
and BNP may have diﬀerent regulation of gene expression
depending on the form and localization of the stress exerted
on the heart [47]. This may explain why in our study
the correlation between serum levels of natriuretic peptides
and echocardiographic dimensions varied under diﬀerent
loading conditions.
The most signiﬁcant limitation to this study is that
the number of patients in each group of patients is small
and therefore we cannot compare the patients undergoing
surgical and percutanoeus treatment. The age range is wide
in patient groups and controls. The controls were examined
only once. However, we assumed that the levels of peptides
would not change signiﬁcantly during one year.
In conclusion, serum levels of both ANPN and NT-
proBNP are higher in patients with ASD or PDA than in
controls. In patients with CoA, ANPN levels are higher
than in controls. After treatment, peptide levels decrease
and some remodeling of the originally loaded ventricle
takes place during within 6–12 months. Natriuretic peptide
levels correlate with echocardiographic ﬁndings and reﬂect
the hemodynamic loading condition. Therefore, natriuretic
peptidesmightbeusefulinthepre-andpostoperativefollow-
up of these patient groups.8 International Journal of Pediatrics
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Figure 4: The z-score (SD) of end-diastolic thickness of interven-
tricular septum (IVSED) in patients with coarctation of the aorta
(CoA) and in controls. Whiskers at the top and bottom of each box
indicate maximum and minimum; the top and bottom of each box
the third and ﬁrst quartiles; line through the box the median. Solid
circle is an outlier.
Acknowledgments
This study was supported by grants from the Finnish
Foundation for Cardiovascular Research, the Foundation for
Pediatric Research, and the special governmental subsidy for
health sciences research, all in Helsinki, Finland.
References
[1] J. P. Goetze, “ProBNP-derived peptides in cardiac disease,”
Scandinavian Journal of Clinical and Laboratory Investigation,
vol. 64, no. 5, pp. 497–510, 2004.
[2] L. B. Cea, “Natriuretic peptide family: new aspects,” Cur-
rent Medicinal Chemistry: Cardiovascular and Hematological
Agents, vol. 3, no. 2, pp. 87–98, 2005.
[3] V. K. Munagala, J. C. Burnett Jr., and M. M. Redﬁeld,
“Thenatriureticpeptidesincardiovascularmedicine,”Current
Problems in Cardiology, vol. 29, no. 12, pp. 707–769, 2004.
[ 4 ] A .J .d eB o l d ,K .K .M a ,Y .Z h a n g,M .L .d eB o l d ,M .B e n s i m o n ,
and A. Khoshbaten, “The physiological and pathophysio-
logical modulation of the endocrine function of the heart,”
Canadian Journal of Physiology and Pharmacology, vol. 79, no.
8, pp. 705–714, 2001.
[5] C. Hall, “NT-ProBNP: the mechanism behind the marker,”
Journal of Cardiac Failure, vol. 11, no. 5, supplement, pp. S81–
S83, 2005.
[6] A. Koch and H. Singer, “Normal values of B type natriuretic
peptide in infants, children, and adolescents,” Heart, vol. 89,
no. 8, pp. 875–878, 2003.
[7] M. Yoshibayashi, T. Kamiya, Y. Saito, et al., “Plasma brain
natriuretic peptide concentrations in healthy children from
birth to adolescence: marked and rapid increase after birth,”
European Journal of Endocrinology, vol. 133, no. 2, pp. 207–
209, 1995.
[8] T. S. Mir, R. Laux, H. H. Hellwege, et al., “Plasma con-
centrations of aminoterminal pro atrial natriuretic peptide
and aminoterminal pro brain natriuretic peptide in healthy
neonates: marked and rapid increase after birth,” Pediatrics,
vol. 112, no. 4, pp. 896–899, 2003.
[9] M. Rauh and A. Koch, “Plasma N-terminal pro-B-type
natriuretic peptide concentrations in a control population of
infants and children [10],” Clinical Chemistry, vol. 49, no. 9,
pp. 1563–1564, 2003.
[ 1 0 ]A .N i r ,B .B a r - O z ,Z .P e r l e s ,R .B r o o k s ,A .K o r a c h ,a n dA .J .
Rein, “N-terminal pro-B-type natriuretic peptide: reference
plasma levels from birth to adolescence. Elevated levels at
birth and in infants and children with heart diseases,” Acta
Paediatrica, vol. 93, no. 5, pp. 603–607, 2004.
[11] J. Weil, F. Bidlingmaier, C. Dohlemann, U. Kuhnle, T. Strom,
and R. E. Lang, “Comparison of plasma atrial natriuretic
peptide levels in healthy children from birth to adolescence
and in children with cardiac diseases,” Pediatric Research, vol.
20, no. 12, pp. 1328–1331, 1986.
[12] S. Matsuoka, Y. Kurahashi, Y. Miki, et al., “Plasma atrial
natriuretic peptide in patients with congenital heart diseases,”
Pediatrics, vol. 82, no. 4, pp. 639–643, 1988.
[13] A. R. Erbay, M. B. Yilmaz, M. Balci, and I. Sabah, “Atrial
natriuretic peptide levels in adult patients before and after
surgery for correction of atrial septal defects: relationship with
atrial arrhythmias,” Clinical Science, vol. 107, no. 3, pp. 297–
302, 2004.
[ 1 4 ]C .G .C o w l e y ,J .D .B r a d l e y ,a n dR .E .S h a d d y ,“ B - t y p e
natriuretic peptide levels in congenital heart disease,” Pediatric
Cardiology, vol. 25, no. 4, pp. 336–340, 2004.
[15] H. Muta, M. Ishii, Y. Maeno, T. Akagi, and H. Kato, “Quan-
titative evaluation of the changes in plasma concentrations
of cardiac natriuretic peptide before and after transcatheter
closure of atrial septal defect,” Acta Paediatrica,v o l .9 1 ,n o .6 ,
pp. 649–652, 2002.
[16] B. Zeevi, I. Gil-Ad, R. Zabreski, et al., “Interventional
catheterization decreases plasma levels of atrial natriuretic
peptide (ANP) in children with congenital heart defects,”
Catheterization and Cardiovascular Diagnosis, vol. 45, no. 1,
pp. 27–32, 1998.
[17] K. M. Borow and R. Karp, “Atrial septal defect—lessons from
the past, directions for the future,” The New England Journal of
Medicine, vol. 323, no. 24, pp. 1698–1700, 1990.
[18] M. Campbell, “Natural history of atrial septal defect,” British
Heart Journal, vol. 32, no. 6, pp. 820–826, 1970.
[19] M. Samanek, “Children with congenital heart disease: proba-
bility of natural survival,” Pediatric Cardiology, vol. 13, no. 3,
pp. 152–158, 1992.
[20] L. Benson and P. McLaughlin, “Coarctation of the aorta,” in
The Natural and Modiﬁed History of Congenital Heart Disease,
R .F r e e d o m ,S .J .Y o o ,H .M i k a i l i a n ,a n dW .G .W i l l i a m s ,E d s . ,
vol. 1, pp. 251–275, Blackwell, New York, NY, USA, 2004.
[21] A. Rothman, “Coarctation of the aorta: an update,” Current
Problems in Pediatric and Adolescent Health Care, vol. 28, no.
2, pp. 33–60, 1998.
[22] C. Kampmann, C. M. Wiethoﬀ, A. Wenzel, et al., “Normal
values of M mode echocardiographic measurements of more
than 2000 healthy infants and children in central Europe,”
Heart, vol. 83, no. 6, pp. 667–672, 2000.International Journal of Pediatrics 9
[23] A. Eerola, E. Jokinen, T. Boldt, and J. Pihkala, “The inﬂuence
of percutaneous closure of patent ductus arteriosus on left
ventricular size and function: a prospective study using two-
and three-dimensional echocardiography and measurements
of serum natriuretic peptides,” Journal of the American College
of Cardiology, vol. 47, no. 5, pp. 1060–1066, 2006.
[24] R. O. Bonow, J. S. Borer, D. R. Rosing, S. L. Bacharach, M. V.
Green, and K. M. Kent, “Left ventricular functional reserve in
adult patients with atrial septal defect: pre- and postoperative
studies,” Circulation, vol. 63, no. 6, pp. 1315–1322, 1981.
[25] K. A. Popio, R. Gorlin, L. E. Teichholz, P. F. Cohn, D. Bechtel,
and M. V. Herman, “Abnormalities of left ventricular function
and geometry in adults with an atrial septal defect. Ventricu-
lographic, hemodynamic and echocardiographic studies,”
American Journal of Cardiology, vol. 36, no. 3, pp. 302–308,
1975.
[26] A. Giardini, P. Moore, M. Brook, V. Stratton, and T. Tacy,
“Eﬀect of transcatheter atrial septal defect closure in children
on left ventricular diastolic function,” American Journal of
Cardiology, vol. 95, no. 10, pp. 1255–1257, 2005.
[ 2 7 ]J .P .H a r t ,S .E .C a b r e r i z a ,R .F .W a l s h ,e ta l . ,“ E c h o c a r d i o -
graphic analysis of ventricular geometry and function during
repair of congenital septal defects,” Annals of Thoracic Surgery,
vol. 77, no. 1, pp. 53–60, 2004.
[28] R. E. Walker, A. M. Moran, K. Gauvreau, and S. D. Colan,
“Evidence of adverse ventricular interdependence in patients
with atrial septal defects,” American Journal of Cardiology, vol.
93, no. 11, pp. 1374–1377, 2004.
[29] C. A. Pedra, J. Pihkala, K. J. Lee, et al., “Transcatheter closure
of atrial septal defects using the Cardio-Seal implant,” Heart,
vol. 84, no. 3, pp. 320–326, 2000.
[30] G. R. Veldtman, V. Razack, S. Siu, et al., “Right ventricular
form and function after percutaneous atrial septal defect
device closure,” Journal of the American College of Cardiology,
vol. 37, no. 8, pp. 2108–2113, 2001.
[ 3 1 ]Z .D .D u ,Q .L .C a o ,P .K o e n i g ,M .H e i t s c h m i d t ,a n dZ .M .
Hijazi, “Speed of normalization of right ventricular volume
overload after transcatheter closure of atrial septal defect in
children and adults,” American Journal of Cardiology, vol. 88,
no. 12, pp. 1450–1453, 2001.
[32] R. A. Meyer, J. C. Korfhagen, W. Covitz, and S. Kaplan, “Long-
term follow-up study after closure of secundum atrial septal
defect in children: an echocardiographic study,” American
Journal of Cardiology, vol. 50, no. 1, pp. 143–148, 1982.
[33] M. Nakazawa, J. M. Jarmakani, M. T. Gyepes, J. V. Prochazka,
S. M. Yabek, and R. A. Marks, “Pre and postoperative ventric-
ular function in infants and children with right ventricular
volume overload,” Circulation, vol. 55, no. 3, pp. 479–484,
1977.
[34] K. L. Wanderman, I. Ovsyscher, and M. Gueron, “Left
ventricular performance in patients with atrial septal defect:
evaluation with noninvasive methods,” American Journal of
Cardiology, vol. 41, no. 3, pp. 487–493, 1978.
[35] A. Eerola, J. I. Pihkala, T. Boldt, I. P. Mattila, T. Poutanen,
and E. Jokinen, “Hemodynamic improvement is faster after
percutaneous ASD closure than after surgery,” Catheterization
and Cardiovascular Interventions, vol. 69, no. 3, pp. 432–441,
2007.
[36] K. Kikuchi, K. Nishioka, T. Ueda, et al., “Relationship
between plasma atrial natriuretic polypeptide concentration
and hemodynamic measurements in children with congenital
heart disease,” Journal of Pediatrics, vol. 111, no. 3, pp. 335–
342, 1987.
[37] T. E. Iivainen, K. W. Groundstroem, J. T. Lahtela, T. J.
Talvensaari, A. Pasternack, and A. Uusitalo, “Serum N-
terminal atrial natriuretic peptide in adult patients late after
surgical repair of atrial septal defect,” European Journal of
Heart Failure, vol. 2, no. 2, pp. 161–165, 2000.
[38] D. Holmgren, A. Westerlind, P. A. Lundberg, and H.
W˚ ahlander, “Increased plasma levels of natriuretic peptide
type BandAinchildren withcongenital heart defects withleft
compared with right ventricular volume overload or pressure
overload,” Clinical Physiology and Functional Imaging, vol. 25,
no. 5, pp. 263–269, 2005.
[39] A. Westerlind, H. W˚ ahlander, G. Lindstedt, P. A. Lundberg,
andD.Holmgren,“Clinicalsignsofheartfailureareassociated
with increased levels of natriuretic peptide types B and A in
children with congenital heart defects or cardiomyopathy,”
Acta Paediatrica, vol. 93, no. 3, pp. 340–345, 2004.
[ 4 0 ] M .C .J o h n s o n ,F .R .G u t i e r r e z ,D .R .S e k a r s k i ,C .M .O n g ,a n d
C.E.Canter,“Comparisonofventricularmassandfunctionin
early versus late repair of coarctation of the aorta,” American
Journal of Cardiology, vol. 73, no. 9, pp. 698–701, 1994.
[41] T. R. Kimball, J. M. Reynolds, W. A. Mays, P. Khoury,
R. P. Claytor, and S. R. Daniels, “Persistent hyperdynamic
cardiovascularstateatrestandduringexerciseinchildrenafter
successful repair of coarctation of the aorta,” Journal of the
American College of Cardiology, vol. 24, no. 1, pp. 194–200,
1994.
[42] L. ´ Y Sigurdard´ ottir and H. Helgason, “Echocardiographic
evaluation of systolic and diastolic function in postoperative
coarctation patients,” Pediatric Cardiology,v o l .1 8 ,n o .2 ,p p .
96–100, 1997.
[43] G. Pacileo, G. Pacileo, C. Pisacane, et al., “Left ventricular
remodeling and mechanics after successful repair of aortic
coarctation,” AmericanJournal of Cardiology,v o l .8 7 ,n o .6 ,p p .
748–752, 2001.
[44] A. Eerola, A. Eerola, A. Eerola, et al., “Left ventricular
hypertrophy persists after successful treatment for coarctation
of the aorta,” Scandinavian Cardiovascular Journal, vol. 41, no.
6, pp. 370–377, 2007.
[45] T. S. Mir, J. Falkenberg, B. Friedrich, et al., “Levels of brain
natriuretic peptide in children with right ventricular overload
duetocongenitalcardiacdisease,”CardiologyintheYoung,vol.
15, no. 4, pp. 396–401, 2005.
[46] W .M.Book,B.J .H ott,andM.M cConnell,“B-typenatriuretic
peptide levels in adults with congenital heart disease and right
ventricular failure,” American Journal of Cardiology, vol. 95,
no. 4, pp. 545–546, 2005.
[47] N. Dzimiri, N. Dzimiri, N. Dzimiri, et al., “Diﬀerential
regulation of atrial and brain natriuretic peptides and its
implications for the management of left ventricular volume
overload,” European Journal of Clinical Investigation, vol. 32,
no. 8, pp. 563–569, 2002.